Gilead Sciences, Inc. (NASDAQ:GILD) Wells Fargo 2024 Healthcare Conference September 4, 2024 11:00 AM ET Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Participants Mohit Bansal - Wells Fargo Mohit Bansal Good morning, my name is Mohit Bansal. I'm one of the biopharma analyst here at Wells Fargo. And this is my third year hosting it. And I think... Andrew Dickinson Third year's [indiscernible]. Mohit Bansal So thank you, Andy, for joining us today. Andrew Dickinson Thank you ...

Gilead Sciences, Inc. (NASDAQ:GILD) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 12:20 PM ET Company Participants Daniel O'Day - Charman & CEO Andrew Dickinson - Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Thanks for joining us, everybody. I'm Terence Flynn, the U.S. biopharma analyst here at Morgan Stanley. Before we get started, for important disclosures, please see the Morgan Stanley research disclosure website at www.morg ...

Gilead Sciences, Inc. (NASDAQ:GILD) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 12:20 PM ET Company Participants Daniel O'Day - Charman & CEO Andrew Dickinson - Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Thanks for joining us, everybody. I'm Terence Flynn, the U.S. biopharma analyst here at Morgan Stanley. Before we get started, for important disclosures, please see the Morgan Stanley research disclosure website at www.morg ...

Merck & Co. MRK and Gilead Sciences Inc. GILD are two pharmaceutical heavyweights whose stocks tell very different stories.Rahway, New Jersey-based Merck just flashed a Death Cross, signaling potential trouble ahead. Foster City, California-based Gilead is basking in a Golden Cross, a sign of bullish momentum.Merck: Treading On Thin IceMerck, known for its diverse lineup of drugs and vaccines, is seeing its stock wobble. Despite a decent climb of 8.72% over the past year, recent technical signals are turnin ...

Sundry Photography When looking at the last few weeks, we can make statements about Gilead Sciences Inc. (NASDAQ:GILD), which we could seldom make in the last few years. Gilead Sciences not only outperformed the market, but we also had a streak of nine up days in a row. Looking at the last three months, Gilead Sciences performed great and especially since the beginning of July 2024, Gilead Sciences started to outperform the S&P 500 (SPY). Data by YCharts My last article about Gilead Sciences was publish ...

Ridofranz/iStock via Getty Images My previous article, “Gilead Sciences: Seriously Undervalued At Peak Pessimism,” caused quite a stir in the comments, particularly from those Seeking Alpha readers who remain pessimistic about Gilead Sciences, Inc.'s (NASDAQ:GILD) business prospects. However, that hasn't stopped the company's stock price from rising more than 23% in less than three months. In this article, I'll present an analysis of the sales of its HIV and oncology franchises, the successes and failur ...

Biotech giant Gilead Sciences, Inc. (GILD) has gained 16.8% in the past three months compared with the industry’s growth of 7.6%. The stock has also outperformed the sector and the S&P 500.The stock’s performance was hit by pipeline setbacks earlier in the year. Nonetheless, this month, Gilead reported better-than-expected second-quarter results and raised its annual earnings guidance. Revenues increased 5% from the year-ago quarter’s level due to high HIV, oncology and liver disease drug sales. Earnings al ...

Gilead Sciences, Inc. (GILD) announced that the FDA has granted accelerated approval to seladelpar for the treatment of primary biliary cholangitis (PBC), in combination with ursodeoxycholic acid (UDCA), in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.The candidate was approved under the brand name Livdelzi.PBC is a rare, chronic, autoimmune disease of the bile ducts that currently has no cure.PBC affects approximately 130,000 Americans, primarily ...

Gilead Sciences says it uncovered a dangerous drug-counterfeiting operation in which its HIV medications were tampered with and improperly resold before reaching patients.The scheme, allegedly run out of two New York City pharmacies, identified Peter Khaim, a twice-convicted medical fraudster, as the mastermind, according to court documents unsealed this month. The company described Khaim as one of the most brazen and largest manufacturers and sellers of counterfeit Gilead medications in the country.Gilead ...

On Thursday, Gilead Sciences, Inc. GILD reported second-quarter revenue of $6.95 billion, beating the consensus of $6.72 billion.Sales increased 5% year over year primarily due to higher product sales in HIV, Liver Disease, and Oncology. Product sales excluding Veklury increased 6% year-over-year to $6.7 billion.Adjusted EPS was $2.01, up from $1.34 a year ago, beating the consensus of $1.60, primarily driven by lower operating expenses and higher revenues.Also Read: Gilead’s $42.5K Priced HIV Drug Could Be ...